ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Dec 30, 2017
Bank Valuations and We're All Market Timers?
President of Investment Research Brian Nelson dives into questions about why an enterprise free cash flow model is not used for banking and insurance entities, and offers up the idea that we all might be market timers. What do you think? Running time: ~14 minutes.
Dec 29, 2017
Valuentum Announcements
We’re excited to usher in the New Year, and we hope you are, too!
Dec 22, 2017
Boeing’s Big Dividend Hike; Potential Deal with Embraer
Image Source: Boeing. We love Boeing. The company has been one of our favorites for years, but its performance during 2017 has simply been amazing. The dividend growth giant upped its payout in a big way recently, too, even as it is reportedly pursuing merger discussions with Embraer.
Dec 20, 2017
Dividends: Costco and Walmart
Image Source: Fiscal Year 2017 Annual Report. The retail sector is undergoing a revolutionary change to its traditional business model of delivering value to customers in a brick-and-mortar format with a tepid nod towards an e-commerce platform. There will inevitably be winners and losers from such a massive paradigm shift to online, but we think Costco and Walmart will be able to adapt effectively, while delivering a tidy dividend to boot. We do not believe Amazon will rule the world.
Dec 17, 2017
Dividend Increases/Decreases for the Week Ending December 15
Let's take a look at companies raising/lowering their dividends this week.
Dec 14, 2017
Comment: Verint's Traditional Free Cash Flow
Image shown: Page 1 of 16, Valuentum's 16-page stock report on Verint (VRNT). Verint is free cash flow positive, implying that non-GAAP earnings adjustments are of high quality.
Dec 12, 2017
CVS Health at the Crossroads, Too Much Debt
Image Source: CVS Health. We have been disappointed with the lack progress displayed by CVS Health thus far in 2017. We knew the business was entering into an earnings trough as a result of key contract losses, but recent events have unfolded that, in our view, have lessened the attractiveness of its business model, to a meaningful degree. Let’s talk more about what’s happening at CVS Health, the changing PBM market, Amazon’s threat, and too much leverage. We’re not overreacting, but we’re not happy either.
Dec 11, 2017
Video: Nelson's Active Management Theorem, Poker and "High Society," Inertia and the Value-Growth Conundrum
President of Investment Research Brian Nelson details his simple new theorem of the stock market that may change everything you believe. Nelson explains using poker as an example, and he goes on to caution about the concept of inertia, and how investing has somehow transformed into a "game" -- if investors truly believe there are 'value' and 'growth' stocks. A must-watch intrigue. Running time: ~11 minutes.
Dec 9, 2017
Addressing the Intricacies of the Dividend Cushion Ratio
The Dividend Cushion ratio continues to build an impressive track record of warning investors of impending dividend cuts, but it’s not perfect. Let’s examine a few recent cases.
Dec 9, 2017
BioMarin Pharmaceuticals: A Rare Drug Powerhouse
Image shown: BioMarin's stock price has had a choppy ride these past couple years. BioMarin continues its impressive string of hits in the rare drug market. We continue to be impressed with the depth of the scientific advances brought forth by the company. An in-depth discussion of BioMarin's pipeline is warranted, in our view, particularly in light of the potential for an expected, upcoming FDA approval.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.